Clinical Trials Logo

Clinical Trial Summary

Lupus anticoagulants (are antiphospholipid antibodies (PSA), the screening of which is done by demonstrating prolongation of coagulation times corrected by the intake of phospholipids (PL). Learned societies (ISTH, CLSI) thus recommend, for the research of LA, to carry out initially two screening tests with a low concentration in PL: a time of diluted Russell viper venom (DRVVT) as well as a time activated partial thromboplastin (TCA). If one of these screening tests is positive, it is recommended to perform a second confirmation test using the same principle (DRVVT or TCA) and containing a higher concentration of PL. The current LA screening method at the Hematology Laboratory of Strasbourg University Hospital includes: a pair of DRVVT screening / confirmation (STA-Staclot DRVV Screen and Confirm, Diagnostica Stago, France) and a screening TCA (PTT-A , Diagnostica Stago, France). This study aims to compare with the current method of the investigators a pair of TCA screening / confirmation (Cephen LS / Cephen, Hyphen Biomed, France).


Clinical Trial Description

n/a


Study Design


NCT number NCT05172778
Study type Observational
Source University Hospital, Strasbourg, France
Contact Agathe HERB, PharmD
Phone 33 3 88 12 75 53
Email agathe.herb@chru-strasbourg.fr
Status Recruiting
Phase
Start date July 30, 2021
Completion date December 31, 2022